Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
Saverio Cinieri(Ospedale A. Perrino), Uğur Çoşkun, Agustí Barnadas, Silvia Lazzarelli(Istituti Ospitalieri di Cremona), Patricia Dodyk, A. Vandebroek, G. Villanova(Pierre Fabre (France)), N. Tubiana-Mathieu(Centre Hospitalier Universitaire de Limoges), Kadri Altundağ(Hacettepe University Hospital), Arlene Chan(Curtin University), Michiel Botha, Daniel Rauch(Washington University in St. Louis)
Cited by 12
Related Papers
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2021|255
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234